Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas.
about
High content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discoveryStructures, targets and recent approaches in anti-leishmanial drug discovery and development.Identification and characterization of genes involved in leishmania pathogenesis: the potential for drug target selection.Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease.Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discoveryGlucose-6-phosphate dehydrogenase of trypanosomatids: characterization, target validation, and drug discoveryExperimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.Multi-Anti-Parasitic Activity of Arylidene Ketones and Thiazolidene Hydrazines against Trypanosoma cruzi and Leishmania spp.Simple dialkyl pyrazole-3,5-dicarboxylates show in vitro and in vivo activity against disease-causing trypanosomatids.Apoptotic marker expression in the absence of cell death in staurosporine-treated Leishmania donovani.Probing druggability and biological function of essential proteins in Leishmania combining facilitated null mutant and plasmid shuffle analyses.Myocardial scars correlate with eletrocardiographic changes in chronic Trypanosoma cruzi infection for dogs treated with Benznidazole.Antiprotozoal activity of dehydroabietic acid derivatives against Leishmania donovani and Trypanosoma cruzi
P2860
Q28485997-43C34ECE-D65B-4D37-B0D4-93785687265EQ35012968-36404540-4CF1-4D3E-8475-9DCF7BF1A8AAQ35430594-C027D6DC-0551-4F83-B4A3-2D71A3E00F8BQ37998091-617BBF85-7B83-4F4A-826D-A9F3987B320AQ38188571-3BE3212A-62FA-49BD-A274-5B2AD0F7AE3FQ38503780-E8CC06E0-5008-43E4-83C8-8F535A53EB80Q38746177-C587D256-8462-44C1-A22A-4250D0996983Q38904942-4C7489B9-16FD-446E-8738-226FB7FCECA2Q40222180-1B2244C6-0990-4A42-8FA3-B15F5922DB8CQ40268471-F6CD5C6E-F707-4F62-982C-2D00705AC5AEQ41453168-F615C772-E1E2-493B-BFC1-2574A12965E0Q42219032-99D8D639-218E-404D-9572-DECA2DBA7A30Q43584085-DADA83CF-8461-418A-9DA9-149F94FE3196Q58848333-0309B17A-B673-44B9-ABA8-E3AAC633C105
P2860
Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Collaborative actions in anti- ...... rs from disease endemic areas.
@en
Collaborative actions in anti- ...... rs from disease endemic areas.
@nl
type
label
Collaborative actions in anti- ...... rs from disease endemic areas.
@en
Collaborative actions in anti- ...... rs from disease endemic areas.
@nl
prefLabel
Collaborative actions in anti- ...... rs from disease endemic areas.
@en
Collaborative actions in anti- ...... rs from disease endemic areas.
@nl
P2093
P356
P1476
Collaborative actions in anti- ...... rs from disease endemic areas.
@en
P2093
Dolores González-Pacanowska
Gerald F Späth
Jean-Claude Dujardin
Ole F Olesen
Simon L Croft
P304
P356
10.1016/J.PT.2010.04.012
P577
2010-06-09T00:00:00Z